Factors Affecting Recruitment of Participants for Studies of Diabetes Technology in Newly Diagnosed Youth with Type 1 Diabetes: A Qualitative Focus Group Study with Parents and Children.

Abstract:

BACKGROUND:Relatively little is known about parents' or children's attitudes toward recruitment for, and participation in, studies of new diabetes technologies immediately after diagnosis. This study investigated factors affecting recruitment of participants for studies in newly diagnosed youth with type 1 diabetes. METHODS:Qualitative focus group study incorporating four recorded focus groups, conducted in four outpatient pediatric diabetes clinics in large regional hospitals in England. Participants comprised four groups of parents (n = 22) and youth (n = 17) with type 1 diabetes, purposively sampled on the basis of past involvement (either participation or nonparticipation) in an ongoing two-arm randomized trial comparing multiple daily injection with conventional continuous subcutaneous insulin infusion regimens from the onset of type 1 diabetes. RESULTS:Stress associated with diagnosis presents significant challenges in terms of study recruitment, with parents demonstrating varied levels of willingness to be approached soon after diagnosis. Additional challenges arise regarding the following: randomization when study arms are perceived as sharply differentiated in terms of therapy effectiveness; burdens arising from study participation; and the need to surrender new technologies following the end of the study. However, these challenges were mostly insufficient to rule out study participation. Participants emphasized the benefits and reassurance arising from support provided by staff and fellow study participants. CONCLUSIONS:Recruitment to studies of new diabetes technologies immediately after diagnosis in youth presents significant challenges, but these are not insurmountable. The stress and uncertainty arising from potential participation may be alleviated by personalized discussion with staff and peer support from fellow study participants.

journal_name

Diabetes Technol Ther

authors

Farrington C,Allen J,Tauschmann M,Randell T,Trevelyan N,Hovorka R

doi

10.1089/dia.2016.0157

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

568-73

issue

9

eissn

1520-9156

issn

1557-8593

journal_volume

18

pub_type

杂志文章
  • Wear and biomechanical characteristics of a novel shear-reducing insole with implications for high-risk persons with diabetes.

    abstract:OBJECTIVE:This study was designed to measure pressure and shear reduction of a novel insole design. METHODS:We compared three multilayer viscoelastic insoles to a novel insole design (Glide-Soft, Xilas Medical, Inc., San Antonio, TX). The bottom pad of each insole was fabricated from firm-density Plastazote [Apex Foot...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2005.7.638

    authors: Lavery LA,Lanctot DR,Constantinides G,Zamorano RG,Athanasiou KA,Agrawal CM

    更新日期:2005-08-01 00:00:00

  • Administration of Biosimilar Insulin Analogs: Role of Devices.

    abstract::With the expiration of patent protection for several originator insulin analog molecules, the availability of insulin analog copies is set to increase. Many regulatory authorities have developed, and continue to refine, guidelines for the approval of biosimilar insulin analogs. Aspects such as the structure, pharmacok...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2016.0263

    authors: Heinemann L,Fritz I,Khatami H,Edelman SV

    更新日期:2017-02-01 00:00:00

  • A dynamic risk measure from continuous glucose monitoring data.

    abstract:BACKGROUND:The quantitative analysis of glucose time-series can greatly help the management of diabetes. In particular, a static nonlinear transformation, which symmetrizes the distribution of glucose levels by bringing them in the so-called risk space, was proposed previously for both self-monitoring blood glucose and...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0006

    authors: Guerra S,Sparacino G,Facchinetti A,Schiavon M,Man CD,Cobelli C

    更新日期:2011-08-01 00:00:00

  • Estimated Lifetime Economic Burden of Type 1 Diabetes.

    abstract:: Background: The financial strain of type 1 diabetes on the United States health care system, patients, and employers underscores the importance of developing novel treatments for the disease. This study estimated the lifetime economic burden attributable to type 1 diabetes...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0398

    authors: Sussman M,Benner J,Haller MJ,Rewers M,Griffiths R

    更新日期:2020-02-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses.

    abstract:BACKGROUND:This exploratory study examined the pharmacokinetics and pharmacodynamics of a Bentley Pharmaceuticals, Inc. (North Hampton, NH) proprietary insulin formulation utilizing CPE-215 technology designed for intranasal administration. METHODS:Eight fasting healthy volunteers (four men, four women; body mass inde...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2005.7.124

    authors: Leary AC,Stote RM,Breedt HJ,O'Brien J,Buckley B

    更新日期:2005-02-01 00:00:00

  • Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours.

    abstract:BACKGROUND:This study assessed the feasibility of a portable bihormonal closed-loop system at home. SUBJECTS AND METHODS:Sixteen pump-treated patients with type 1 diabetes received 48 h of closed-loop therapy with a telemonitored insulin- and glucagon-delivering closed-loop system and 48 h of patient-managed open-loop...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2013.0166

    authors: van Bon AC,Luijf YM,Koebrugge R,Koops R,Hoekstra JB,DeVries JH

    更新日期:2014-03-01 00:00:00

  • The use of continuous glucose monitoring in patients with type 2 diabetes.

    abstract::Since the late 1970s, self-monitoring of blood glucose has been the standard for assessing daily glycemic control. The first continuous glucose monitor became available in 1999. Numerous clinical trials have documented the benefits of continuous glucose monitoring (CGM) in patients with type 1 diabetes mellitus (DM). ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2011.0086

    authors: Meade LT

    更新日期:2012-02-01 00:00:00

  • Effectiveness of virtual reality using video gaming technology in elderly adults with diabetes mellitus.

    abstract:BACKGROUND:Diabetes in elderly adults is associated with an increased risk of fall. The aim of study was to determine whether a virtual reality exercise (VRE) program would improve balance, strength, gait, and falls efficacy in elderly adults with diabetes. SUBJECTS AND METHODS:Fifty-five subjects with diabetes mellit...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2013.0050

    authors: Lee S,Shin S

    更新日期:2013-06-01 00:00:00

  • Development of optimal kids insulin dosing system formulas for young children with type 1 diabetes mellitus.

    abstract:OBJECTIVE:This study was designed to develop predictive formulas for precise insulin dosing in young children with type 1 diabetes (T1DM). RESEARCH DESIGN AND METHODS:Consecutive 1-year data from a group of 14 young patients (eight girls, six boys) 3.9 ± 0.8 years old with diabetes duration of 2.0 ± 0.8 years, transit...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0184

    authors: Alemzadeh R,Hoffmann RG,Dasgupta M,Parton E

    更新日期:2012-05-01 00:00:00

  • Self-monitoring of blood glucose in diabetes: from evidence to clinical reality in Central and Eastern Europe--recommendations from the international Central-Eastern European expert group.

    abstract::Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence sugg...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2013.0302

    authors: Czupryniak L,Barkai L,Bolgarska S,Bronisz A,Broz J,Cypryk K,Honka M,Janez A,Krnic M,Lalic N,Martinka E,Rahelic D,Roman G,Tankova T,Várkonyi T,Wolnik B,Zherdova N

    更新日期:2014-07-01 00:00:00

  • Role of continuous subcutaneous insulin infusion in patients with recalcitrant diabetes in South India.

    abstract:BACKGROUND:We aimed to assess the effect of continuous subcutaneous insulin infusion (CSII) therapy in patients with "recalcitrant diabetes" whose glycemia had not been controlled adequately with multiple daily injections of insulin or insulin plus oral hypoglycemic agents. PATIENTS AND METHODS:We retrospectively anal...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0066

    authors: Sudhakaran C,Anjana RM,Rao K,Unnikrishnan R 1st,Suresh T,Mohan V

    更新日期:2009-11-01 00:00:00

  • Diabetes and the World Wide Web.

    abstract::The World Wide Web has become remarkably quickly an alternative source of information for patients and their relatives, as well as students and health-care professionals. A whole plethora of websites and Internet-based applications related to diabetes have appeared in recent years. In this column, selected issues surr...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2005.7.225

    authors: Lehmann ED

    更新日期:2005-02-01 00:00:00

  • Human factors research applied: the development of a personal touch screen insulin pump and users' perceptions of actual use.

    abstract:BACKGROUND:A brief history of the field of human factors research is covered, along with how this discipline is leveraged within medical device companies, to eliminate design flaws in products, in order to make them safe and effective for human use. The way in which human factors research was used to develop the t:slim...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2013.0098

    authors: Schaeffer NE

    更新日期:2013-10-01 00:00:00

  • Characterization of Daily Glycemic Variability in Subjects with Type 1 Diabetes Using a Mixture of Metrics.

    abstract:: Background: Glycemic variability (GV) is an important component of glycemic control for patients with type 1 diabetes (T1D). The inadequacy of existing measurements lies in the fact that they view the variability from different aspects, so that no consensus has been reache...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0250

    authors: Zheng F,Jalbert M,Forbes F,Bonnet S,Wojtusciszyn A,Lablanche S,Benhamou PY

    更新日期:2020-04-01 00:00:00

  • Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study.

    abstract:BACKGROUND:This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform s...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2012.0051

    authors: Bergenstal RM,Bode BW,Tamler R,Trence DL,Stenger P,Schachner HC,Fullam J,Pardo S,Kohut T,Fisher WA

    更新日期:2012-10-01 00:00:00

  • Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

    abstract:OBJECTIVE:To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). METHODS:Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) and completed a 2-week ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0264

    authors: Forlenza GP,Pinhas-Hamiel O,Liljenquist DR,Shulman DI,Bailey TS,Bode BW,Wood MA,Buckingham BA,Kaiserman KB,Shin J,Huang S,Lee SW,Kaufman FR

    更新日期:2019-01-01 00:00:00

  • In vivo glucose monitoring using dual-wavelength polarimetry to overcome corneal birefringence in the presence of motion.

    abstract:OBJECTIVE:Over the past 35 years considerable research has been performed toward the investigation of noninvasive and minimally invasive glucose monitoring techniques. Optical polarimetry is one noninvasive technique that has shown promise as a means to ascertain blood glucose levels through measuring the glucose conce...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2012.0070

    authors: Pirnstill CW,Malik BH,Gresham VC,Coté GL

    更新日期:2012-09-01 00:00:00

  • Automatic learning algorithm for the MD-logic artificial pancreas system.

    abstract:BACKGROUND:Applying real-time learning into an artificial pancreas system could effectively track the unpredictable behavior of glucose-insulin dynamics and adjust insulin treatment accordingly. We describe a novel learning algorithm and its performance when integrated into the MD-Logic Artificial Pancreas (MDLAP) syst...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0216

    authors: Miller S,Nimri R,Atlas E,Grunberg EA,Phillip M

    更新日期:2011-10-01 00:00:00

  • Minimization of Hypoglycemia as an Adverse Event During Insulin Infusion: Further Refinement of the Yale Protocol.

    abstract:BACKGROUND:The management of hyperglycemia in the intensive care unit has been a controversial topic for more than a decade, with target ranges varying from 80-110 mg/dL to <200 mg/dL. Multiple insulin infusion protocols exist, including several computerized protocols, which have attempted to achieve these targets. Imp...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2016.0101

    authors: Marvin MR,Inzucchi SE,Besterman BJ

    更新日期:2016-08-01 00:00:00

  • Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes.

    abstract:BACKGROUND:There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin pump) therapy in children. METHODS:Charts from 291 youth with type 1 diabetes (T1D) who were treated with CSII therapy for at least 1 year were reviewed. Data analysis included hemoglobin ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2007.0214

    authors: Scrimgeour L,Cobry E,McFann K,Burdick P,Weimer C,Slover R,Chase HP

    更新日期:2007-10-01 00:00:00

  • Magnitude and determinants of ocular morbidities among persons with diabetes in a project in Ahmedabad, India.

    abstract:BACKGROUND:Visual disabilities due to diabetes are on the rise, especially in urban areas of developing countries. Proper health planning will need evidence-based information. STUDY DESIGN AND METHODS:We estimated the prevalence and identified the determinants of eye complications among persons with diabetes screened ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0033

    authors: Vyas U,Khandekar R,Trivedi N,Desai T,Danayak P

    更新日期:2009-09-01 00:00:00

  • Biochemical stabilization of glucagon at alkaline pH.

    abstract:BACKGROUND:For patients with type 1 diabetes mellitus, a bihormonal artificial endocrine pancreas system utilizing glucagon and insulin has been found to stabilize glycemic control. However, commercially available formulations of glucagon cannot currently be used in such systems because of physical instability characte...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2014.0047

    authors: Caputo N,Jackson MA,Castle JR,El Youssef J,Bakhtiani PA,Bergstrom CP,Carroll JM,Breen ME,Leonard GL,David LL,Roberts CT Jr,Ward WK

    更新日期:2014-11-01 00:00:00

  • Insulin Pump Settings During Breastfeeding in Women with Type 1 Diabetes.

    abstract:: Background: We aimed to explore insulin pump settings in breastfeeding women with type 1 diabetes. Methods: Thirteen unselected breastfeeding women with type 1 diabetes on insulin pump therapy were included consecutively from A...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0280

    authors: Nørgaard SK,Nørgaard K,Roskjær AB,Mathiesen ER,Ringholm L

    更新日期:2020-04-01 00:00:00

  • Study of Insulin Requirement Modeling in Hospitalized Elderly Patients with Type 2 Diabetes at a Late Stage of Stepwise Escalation Therapy.

    abstract:BACKGROUND:This study explored the relationships between exogenous insulin requirements and endogenous variables in elderly patients with type 2 diabetes (T2D). SUBJECTS AND METHODS:Patients with T2D 65 years of age or older were enrolled for a short hospitalization period in order to start or change their basal-bolus...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2015.0044

    authors: Nourizadeh-Sedaghati A,Herbin M,Lukas-Croisier C,Novella JL,Delemer B

    更新日期:2016-05-01 00:00:00

  • Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.

    abstract:: Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0316

    authors: Bayona Cebada A,Nattero-Chávez L,Alonso Díaz S,Escobar-Morreale HF,Luque-Ramírez M

    更新日期:2020-03-01 00:00:00

  • The Value of Automated Diabetic Retinopathy Screening with the EyeArt System: A Study of More Than 100,000 Consecutive Encounters from People with Diabetes.

    abstract:: Background: Current manual diabetic retinopathy (DR) screening using eye care experts cannot scale to screen the growing population of diabetes patients who are at risk for vision loss. EyeArt system is an automated, cloud-based artificial intelligence (AI) eye screening t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0164

    authors: Bhaskaranand M,Ramachandra C,Bhat S,Cuadros J,Nittala MG,Sadda SR,Solanki K

    更新日期:2019-11-01 00:00:00

  • The emergence of biosimilar insulin preparations--a cause for concern?

    abstract::Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2012.0105

    authors: Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

    更新日期:2012-11-01 00:00:00

  • The Impact of Short-Term Professional Continuous Glucose Monitoring on Glycemic Control Via Lifestyle Improvement.

    abstract:BACKGROUND:The efficacy of short-term professional continuous glucose monitoring (CGM) for glycemic control in patients with diabetes remains unclear. METHODS:We performed a 3-month study to evaluate the benefits of CGM in 64 patients. RESULTS:The overall glycemic control of patients who underwent CGM improved signif...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0164

    authors: Shibusawa R,Yamada E,Okada S,Nakajima Y,Bastie CC,Yamada M

    更新日期:2018-09-01 00:00:00

  • Determining clinical and psychological benefits and barriers with continuous glucose monitoring therapy.

    abstract:BACKGROUND:Preventing the complications of diabetes requires tight control and minimizing blood glucose fluctuation. Pursuing these goals increases the risk of severe hypoglycemia. The authors hoped to identify if using continuous glucose monitoring (CGM) decreased the incidence of severe hypoglycemia, resulted in less...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0121

    authors: Halford J,Harris C

    更新日期:2010-03-01 00:00:00

  • Evaluation of a new blood glucose monitoring system with auto-calibration.

    abstract:BACKGROUND:The Ascensia CONTOUR System (Bayer HealthCare LLC, Elkhart, IN) is a new blood glucose (BG) monitoring system (BGMS) that uses glucose dehydrogenase chemistry and that combines low sample volume, fast response time, an auto-control marking feature, and an auto-calibration function in a small package. METHOD...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2005.7.283

    authors: Kilo C,Pinson M,Joynes JO,Joseph H,Monhaut N,Parkes JL,Baum J

    更新日期:2005-04-01 00:00:00